Cargando…
Impact of a New Reimbursement Program on Hepatitis B Antiviral Medication Cost and Utilization in Beijing, China
BACKGROUND: Hepatitis B virus (HBV) infection is a significant clinical and financial burden for chronic hepatitis B (CHB) patients. In Beijing, China, partial reimbursement on antiviral agents was first implemented for the treatment of CHB patients in July 1, 2011. AIMS: In this study, we describe...
Autores principales: | Qiu, Qian, Li, Yan, Duan, Xiao-wan, Yang, Li-kun, Chen, Yu, Li, Hui, Wang, Li, Duan, Zhong-ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199609/ https://www.ncbi.nlm.nih.gov/pubmed/25329072 http://dx.doi.org/10.1371/journal.pone.0109652 |
Ejemplares similares
-
Cost-utility analysis of newborn hepatitis B immunization in Beijing
por: Guo, Yiwei, et al.
Publicado: (2020) -
Success of Big Infectious Disease Reimbursement Policy in
China
por: Nie, Kun-xi, et al.
Publicado: (2020) -
A Simple Diagnosis-Related Groups-Based Reimbursement System Is Cost Ineffective for Elderly Patients With Displaced Femoral Neck Fracture Undergoing Hemiarthroplasty in Beijing
por: Peng, Hui-ming, et al.
Publicado: (2021) -
Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces
por: Zhou, Hai-yang, et al.
Publicado: (2016) -
TAILORED ACTIVITY PROGRAM (TAP) COSTS: OPPORTUNITIES TO STREAMLINE DELIVERY AND PURSUE REIMBURSEMENT
por: Pizzi, Laura T, et al.
Publicado: (2019)